Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytarabine dose comparison in induction and consolidation therapy for acute myeloid leukemia
ChiCTR2000032790Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Changcheng
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cytarabine and idarubicin in acute myeloid leukemia (AML) (4 arms), sponsored by Zhengzhou Changcheng. Primary endpoints: Event-free survival and Relapse-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
cytarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2000032790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032790.